SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED announced upcoming presentations of preclinical data for…

HUTCHMED (China) Limited · PRESS-RELEASE filed Apr 8, 2026 at 20:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Apr 8, 2026 at 20:00 ET

HUTCHMED announced upcoming presentations of preclinical data for HMPL-A580, a first-in-class antibody-targeted therapy conjugate (ATTC), and updated clinical results for surufatinib combinations at the AACR 2026 meeting. The data highlight the novel mechanism and anti-tumor activity of HMPL-A580 in EGFR-expressing tumors and provide updates on ongoing trials in gastrointestinal and pancreatic cancers.

  • Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR ATTC, will be presented at AACR 2026, showing potent and selective inhibition of tumor cell proliferation in EGFR-expressing models.
  • HMPL-A580 demonstrated dose-dependent anti-tumor activity in xenograft models and favorable pharmacokinetics in monkeys, supporting its potential as a targeted therapy with improved safety over existing PAM inhibitors.
  • Updated Phase Ib/II data for surufatinib plus sintilimab and capecitabine in metastatic small bowel and appendiceal carcinoma will be presented.
  • Exploratory Phase II data on surufatinib combined with gemcitabine/nab-paclitaxel in pancreatic cancer following induction therapy will also be shared.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access